140 related articles for article (PubMed ID: 22593455)
1. Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.
Schoenfeld JD; Odejide OO; Wirth LJ; Chan AW
Anticancer Res; 2012 May; 32(5):1743-6. PubMed ID: 22593455
[TBL] [Abstract][Full Text] [Related]
2. Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma.
Nachalon Y; Stern-Shavit S; Bachar G; Shvero J; Limon D; Popovtzer A
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1128-32. PubMed ID: 26512447
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
Chintakuntlawar AV; Yin J; Foote RL; Kasperbauer JL; Rivera M; Asmus E; Garces NI; Janus JR; Liu M; Ma DJ; Moore EJ; Morris JC; Neben-Wittich M; Price DL; Price KA; Ryder M; Van Abel KM; Hilger C; Samb E; Bible KC
Thyroid; 2019 Nov; 29(11):1615-1622. PubMed ID: 31595822
[No Abstract] [Full Text] [Related]
4. Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
Chi KH; Liao CS; Chang CC; Ko HL; Tsang YW; Yang KC; Mehta MP
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):188-93. PubMed ID: 20133077
[TBL] [Abstract][Full Text] [Related]
5. Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
Lee JO; Lee KW; Kim CJ; Kim YJ; Lee HE; Kim H; Kim JH; Bang SM; Kim JS; Lee JS
Jpn J Clin Oncol; 2009 Mar; 39(3):183-5. PubMed ID: 19168875
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
[TBL] [Abstract][Full Text] [Related]
7. Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03).
Jakob J; Simeonova A; Kasper B; Ronellenfitsch U; Rauch G; Wenz F; Hohenberger P
Radiat Oncol; 2016 Jun; 11():77. PubMed ID: 27255678
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
9. The role of external beam radiation and targeted therapy in thyroid cancer.
Brierley J; Sherman E
Semin Radiat Oncol; 2012 Jul; 22(3):254-62. PubMed ID: 22687950
[TBL] [Abstract][Full Text] [Related]
10. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.
Foote RL; Molina JR; Kasperbauer JL; Lloyd RV; McIver B; Morris JC; Grant CS; Thompson GB; Richards ML; Hay ID; Smallridge RC; Bible KC
Thyroid; 2011 Jan; 21(1):25-30. PubMed ID: 21162687
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
12. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
13. Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.
Kaldrymides P; Kostoglou-Athanassiou I; Gkountouvas A; Veniou E; Ziras N
Endocrine; 2010 Feb; 37(1):6-10. PubMed ID: 20963554
[TBL] [Abstract][Full Text] [Related]
14. [Use of sunitinib in metastatic renal cell carcinoma patients with poor prognosis].
Timofeev IV; Demidov LV; Petenko NN
Vopr Onkol; 2011; 57(1):50-4. PubMed ID: 21598708
[TBL] [Abstract][Full Text] [Related]
15. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival.
Haigh PI; Ituarte PH; Wu HS; Treseler PA; Posner MD; Quivey JM; Duh QY; Clark OH
Cancer; 2001 Jun; 91(12):2335-42. PubMed ID: 11413523
[TBL] [Abstract][Full Text] [Related]
16. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
[TBL] [Abstract][Full Text] [Related]
17. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012.
Baek SK; Lee MC; Hah JH; Ahn SH; Son YI; Rho YS; Chung PS; Lee YS; Koo BS; Jung KY; Lee BJ
Head Neck; 2017 Jan; 39(1):133-139. PubMed ID: 27534388
[TBL] [Abstract][Full Text] [Related]
18. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
Bugalho MJ; Domingues R; Borges A
Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
[TBL] [Abstract][Full Text] [Related]
19. A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?
Jafri M; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E42-4. PubMed ID: 19692324
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib effective for rare thymus cancer.
Cancer Discov; 2015 Apr; 5(4):340. PubMed ID: 25680712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
